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a serious problem, especially after transplantation from
unrelated or HLA-mismatched donors. Heterogeneity
regarding patient selection, transplantation procedures and
study endpoints hamper the interpretation of the available
data.We therefore initiated a prospective trial to evaluate the
results of HSCT in a standardised setting.
From September 2003 through September 2010, 471
children with ALL in ﬁrst, second or subsequent remission
(229 in CR1, 242  CR2) received an allogeneic HSCT from an
HLA-matched sibling (MSD), an HLA-matched family/unre-
lated donor (MD) or, for patients with very high-risk disease,
an HLA-mismatched donor (MMD) after conditioning with
total body irradiation (TBI) and etoposide or a chemo-
therapy-only regimen. Two high risk groups with indication
for an HSCT were deﬁned according to results with conven-
tional chemotherapy: “high relapse risk group” (HRR) and
“very high relapse risk group” (VHRR). HRR was deﬁned by
response to front line chemotherapy, amount of minimal
residual disease (MRD), phenotype of leukemia and/or time
and site of relapse
At a median observation time of 3 years, the 4-year
probability of disease-free survival (pDFS) after MD-HSCT
was equivalent to that of MSD-HSCT (68% vs. 71%; n.s.).
Transplant-related mortality (TRM) after 3 years was 5% for
MSD and 10% for MD HSCT (n.s.). Acute GvHD grade I/II
occurred in 274 pts (58%) with no difference between MSD
and MD or MMD,117 evaluable pts did not develop any acute
GvHD (24%). Grade III and IV aGvHD occurred in 10% of all
patients with no difference according to donor type, stem
cell source, patient's age or gender matching.
Forty percent of 439 evaluable patients developed cGVHD.
The 2-year cumulative incidence of extensive chronic GvHD
was 16% after MSD and 2% after MD HSCT (P < .001). After
MSD-HSCT, age >10 years (29% vs. 4%), transplantation of
PBSC compared to BM (50% vs. 14%) and remission status >
CR1 (21% vs. 11%) negatively inﬂuenced the 2 years cumula-
tive incidence of extensive cGVHD. Gender match of donor/
recipient, year of HSCT, phenotype, and CMV status did not
inﬂuence the incidence and severity of cGVD after MSD-
HSCT. After MD-HSCT, the 2 year cumulative incidence of
cGVHDwas only 5%with no difference between BM and PBSC
or HLA disparities (9/10 or 10/10 matches).
The 3-year cumulative incidence of relapse was 21% after
MSD-HSCT, and 19% after MD-HSCT (n.s.). For patients with
VHRR the results forMD/MSDHSCT (n¼232)were signiﬁcantly
superior to those of MMD HSCT (n¼46) (3-year pDFS 65% vs.
31%; P < .001; 3-year incidence of TRM 10% vs, 26%; P < .001).
Allogeneic HSCT from HLA-matched donors is equivalent
to HSCT from HLA-identical sibling donors in children with
ALL.234
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Allogeneic SCT is curative therapy for patients (pts) with
AML andMDS. However, relapsed disease continues to be the
most common reason for treatment failure. Treatment
options range from supportive care alone to chemotherapy
and donor lymphocyte infusion (DLI) and up to a second SCT
from the same or a different donor. However, the mosteffective therapy is controversial and treatment results are
often poor. Over the last 6 years our policy was to offer
a second SCT from a different donor to pts who had a second
donor available and were in relatively good medical status,
most often after an attempt for remission induction with
intensive chemotherapy. There were 129 relapses of AML/
MDS after SCT during this period, and 26 pts (20%) were able
to proceed to a second SCT from a different donor. The
median age at second SCT was 51 years (19-78). 20 pts were
initially given SCT from a matched sibling, 12 were re-trans-
planted from a second sibling and 8 from an unrelated donor.
Six pts were initially transplanted from an unrelated donor
and re-transplanted from a different unrelated donor. The
initial conditioning regimenwasmyeloablative (MAC, n¼10),
reduced-toxicity (RTC, n¼12) or reduced-intensity (n¼4). The
second regimen was most often ﬂudarabine and treosulfan
(FT, n¼15) for those not previously given treosulfan,
including all previouslyMAC recipients. Other regimenswere
ﬂudarabine/ busulfan (n¼7) or FLAMSA (n¼4). The median
time from the ﬁrst SCT to relapsewas 12months (2monthse
9 years), 7 within 6 months. The median time from ﬁrst
relapse to second SCT was 3 months (range, 1-41 months). 10
pts were in remission at second SCT with prior therapy, 9
were chemo-refractory and 7 were re-transplanted with no
attempts of re-induction. The median follow-up of surviving
pts is 14months (range, 2-77). 24 pts engrafted in amedian of
13 days (range, 9-26). 2 pts died early from infections and 2
fromGVHD and the 2-year cumulative incidence of NRMwas
16% (95%CI, 6-38). 13 pts relapsed after second SCT, 2-year
cumulative incidence 52% (95%CI, 34-77), 10 of them died.
The estimated 2-year OS is 37% (95%CI, 14-60) and the 2-year
disease-free survival is 33% (95%CI, 13-53). Pts re-trans-
planted in chemo-sensitive or untreated relapse had a better
outcome than thosewith chemo-refractory relapse, 2 year OS
49% and 17%, respectively (P ¼ .05). Pts given FT for second
SCT also fared better than the other regimens, 2-year OS 65%
and 18%, respectively (P ¼ .01). 3 of 7 pts with relapse less
than 6 months after SCT are long-term survivors after second
SCT. In conclusion, a second SCT from a different donor is
feasible in a subset of pts with AML and MDS relapsing after
SCT. Toxicity with the new RTC regimens, such as treosulfan-
based is acceptable. This is a promising option for pts able to
be successfully re-induced or re-transplanted early with
a pre-identiﬁed second donor. These observations merit
further conﬁrmation in larger studies.235
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Introduction: Refractory acute myeloid leukemia (AML) is
incurable unless allogeneic stem cell transplant (HCT) is
performed. Remission or bone marrow aplasia is not attain-
able in many and thus they do not proceed to HCT. Clofar-
abine has been used in these patients but may be associated
with increased risk of fungal infection and veno occlusive
disease (VOD) and is expensive. In refractory AML patients
who fail at least one prior salvage therapy, we administer
clofarabine with plan for HCT in bone marrow aplasia. This
study reviews outcome in these patients. The ability of clo-
farabine to achieve aplasia (with or without residual AML) ,
